From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease.

Obicetrapib was associated with a numerically lower incidence of MACEs over 12 months (3.9% versus 5.0%; HR, 0.77 [95% CI, 0.54–1.11]; P =0.16); however, this did not reach statistical significance. 27 Importantly, obicetrapib significantly reduced coronary events (coronary heart disease death, myocardial infarction, or revascularization: HR, 0.68 [95% CI, 0.46–1.00]; P =0.048) during the second 6 months of treatment.

also in 111,027 other papers